
In 2017, we received funding from CIHR’s Partnership for Health Systems Improvement initiative for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) collaboration. This collaboration will develop a framework for the generation and use of Real World Evidence (RWE) for cancer drug funding decisions in Canada.
The CanREValue collaboration brings together key stakeholders including ARCC, CADTH/ pCODR, CAPCA, Health Canada, INESSS, Ministries/departments of Health, pCPA, PMPRB, and provincial cancer agencies from across Canada. By providing a platform for stakeholders to discuss their needs and existing evidence gaps, the CanREValue collaboration will enable knowledge exchange, and address policy relevant research questions.
Contact us: CanREValue@cc-arcc.ca
What’s New


Welcome to the CanREValue Website
Recent Projects
Patient perspectives of Value Frameworks used to Guide Oncology Treatment DecisionsMay 1, 2021 - 12:27 pm
Understanding British Columbia cancer patients’ experiences with virtual health before and during the COVID-19 pandemicMay 1, 2021 - 11:53 am
Benchmarking End of Life Quality Indicators by Tumor Type & Describing models of palliative care across CanadaApril 1, 2021 - 8:56 am
Evaluation of the systemic cancer therapy volume-outcome association: a population-based study to inform the optimal provincial organization and delivery of systemic cancer therapyFebruary 1, 2021 - 12:20 pm
Login
Connect With Us!
RECENT POSTS
CPAC is hiring: Lead, French Translation and Bilingual Project CoordinatorNovember 22, 2023 - 8:19 am
Canadian Cancer Statistics 2023November 9, 2023 - 7:48 am
CCS: Advancing Health Equity Through Cancer Information and Support Services: Report on communities that are underservedNovember 6, 2023 - 11:06 am
CPAC is Hiring – Lead, Research and Data PartnershipsOctober 31, 2023 - 9:52 am